Cue Biopharma (CUE)

• Market cap: $135M
• 1 day: 3.44%
• 5 days: -10.17%
• 1 month: -19.49%
• 3 months: -31.03%
• 6 months: -45.17%
• Year to date: 84.09%
• 1 year: -13.27%
• 5 years: -95.77%
• 10 years: -94.66%
• Sector: Healthcare
• Industry: Biotechnology

About: Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.

Employees: 29